BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
EPKINLY (epcoritamab-bysp) by Genmab is cd20-directed antibody interactions [moa]. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPKINLY (epcoritamab-bysp) is a bispecific CD20-directed CD3 T cell engager approved in May 2023 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It works by simultaneously binding CD20 on B-cell lymphoma cells and CD3 on T cells, redirecting patient immune cells to attack cancer. Administered subcutaneously, it represents a novel approach to hematologic malignancy treatment.
Growth
Early-stage growth product with expanding adoption in relapsed/refractory DLBCL; moderate competitive pressure (30%) suggests opportunity for team expansion in medical affairs and clinical operations.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Bispecific CD20-directed CD3 T Cell Engager
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Genmab is hiring 3 roles related to this product
Worked on EPKINLY at Genmab? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.